Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Preferred Stock Liabilities (2023 - 2025)

Rein Therapeutics (RNTX) has disclosed Preferred Stock Liabilities for 3 consecutive years, with $45.0 million as the latest value for Q4 2025.

  • Quarterly Preferred Stock Liabilities changed 0.0% to $45.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $45.0 million for FY2025, 0.0% changed from the prior year.
  • Preferred Stock Liabilities for Q4 2025 was $45.0 million at Rein Therapeutics, roughly flat from $45.0 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $91.4 million in Q4 2023, with the low at $45.0 million in Q2 2024.
  • Average Preferred Stock Liabilities over 3 years is $50.3 million, with a median of $45.0 million recorded in 2024.
  • The sharpest move saw Preferred Stock Liabilities crashed 50.77% in 2024, then changed 0.0% in 2025.
  • Over 3 years, Preferred Stock Liabilities stood at $91.4 million in 2023, then crashed by 50.77% to $45.0 million in 2024, then changed by 0.0% to $45.0 million in 2025.
  • According to Business Quant data, Preferred Stock Liabilities over the past three periods came in at $45.0 million, $45.0 million, and $45.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.